Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis

Authors: Mishi Kaushal Wasson, Pradeep Singh Chauhan, L. C. Singh, Dheeraj Katara, Jagannath Dev Sharma, Eric Zomawia, Amal Kataki, Sujala Kapur, Sunita Saxena

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

Polymorphisms in DNA repair and cell cycle genes contribute to increased breast cancer (BC) risk. Their association and interaction in relation to betel quid and tobacco chewing habits need exhaustive multi-analytical investigation to explain BC predisposition due to DNA damage. Polymorphism in TP53-72Arg>Pro, RAD51-135G>C, BRCA2, and CCND1-G870A were examined in 204 BC cases and 217 controls from Northeast Indian population. Multifaceted analytic approaches were used to explore relationships between polymorphisms, tobacco history, and BC susceptibility. Betel quid chewing was identified as the predominant risk factor. CCND-AA and dominant model showed protection towards BC in betel quid chewer (BQC) [(0.28 (0.10–0.77), 0.01 and 0.32 (0.12–0.81), 0.01)] and non-betel quid chewers (NBQC) [(0.26 (0.09–0.78), 0.01 and 0.37 (0.16–0.87), 0.02)]. TP53-Pro/Pro genotype showed protection towards BC in NBQC (0.29 (0.10–0.81), p = 0.01) and (0.51 (0.32–0.80), p = 0.003, respectively). RAD51-C allele was associated with BC risk (2.03 (1.26–3.30) 0.002) in BQC. Two BQC cases had BRCA2 8415G>T:K2729N mutation in Exon18. MDR analysis showed best four locus model with TBA 0.6765 (0.005) and CVC of 10/10 in NBQC. Interaction diagram concurred the interactions between TP53 and RAD51 (1.32 %) with independent effect (1.89 %) of CCND1in NBQC. In CART analysis, BQC with CCND1 GG genotype were at risk (OR = 33.0; 95 % CI = 6.08–179.07), p < 0.001) followed by combination of BQC, CCND1, No-Smk, and Alc (OR = 42.00; 95 % CI = 5.11–345.11, p < 0.001). Risk was also observed in BQC, CCND1, No-Smk, Non-Alc, and TP53 combination (OR = 14.84; 95 % CI = 3.13–70.34, p < 0.001) and BQC, CCND1, No-Smk, Non-Alc, TP53 (OR = 9.40; 95 % CI = 1.99–44.34, p < 0.001). NBQC group showed risk with combination of NBQC and TP53 (OR = 5.54; 95 % CI = 1.11–27.42, p = 0.03). Genetic variants in DNA repair and cell cycle genes contribute to BC risk through gene–gene and gene–environmental interactions.
Appendix
Available only for authorised users
Literature
1.
Gajalakshmi V, Mathew A, Brennan P, Rajan B, Kanimozhi VC, Mathews A, et al. Breastfeeding and breast cancer risk in India: a multicenter case-control study. Int J Cancer. 2009;125:662–5.CrossRefPubMed
2.
3.
Kaushal M, Mishra AK, Raju BS, Ihsan R, Chakraborty A, Sharma J, et al. Betel quid chewing as an environmental risk factor for breast cancer. Mutat Res. 2010;703:143–8.CrossRefPubMed
4.
Kaushal M, Mishra AK, Sharma J, Zomawia E, Kataki A, Kapur S, et al. Genomic alterations in breast cancer patients in betel quid and non betel quid chewers. PLoS One. 2012;7:e43789.PubMedCentralCrossRefPubMed
5.
Martin MB, Reiter R, Johnson M, Shah MS, Iann MC, Singh B, et al. Effects of tobacco smoke condensate on estrogen receptor-alpha gene expression and activity. Endocrinology. 2007;148:4676–86.CrossRefPubMed
6.
Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, Lohman K, et al. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:1200–4.PubMed
7.
Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10:2675–80.CrossRefPubMed
8.
Sliwinski T, Renata Krupa R, Majsterek I, Rykala J, Kolacinska A, Morawiec Z, et al. Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res Treat. 2005;94:105–9.CrossRefPubMed
9.
Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489–500.CrossRefPubMed
10.
Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol. 2006;24:5645–54.CrossRefPubMed
11.
Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A. 2001;98:3232–6.PubMedCentralCrossRefPubMed
12.
Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F, et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 2002;21:1928–33.CrossRefPubMed
13.
Srivastava A, Sharma KL, Srivastava N, Misra S, Mittal B. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PLoS One. 2012;7:e40162.PubMedCentralCrossRefPubMed
14.
Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, et al. Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One. 2011;6:e29431.PubMedCentralCrossRefPubMed
15.
Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis. 2004;19:251–62.CrossRefPubMed
16.
Chatterjee A, Deb S. Genotoxic effect of arecoline given either by the peritoneal or oral route in murine bone marrow cells and the influence of N-acetylcysteine. Cancer Lett. 1999;139:23–31.CrossRefPubMed
17.
Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;116:571–5.CrossRefPubMed
18.
Hong Y, Eu KW, Seow-Choen F, Fook-Chong S, Cheah PY. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41:1037–44.CrossRefPubMed
19.
Jia A, Gong J, Li Y, Hao Z, Chang X, Dai F, et al. GG genotype of cyclin D1 G870A polymorphism is associated with non-cardiac gastric cancer in a high-risk region of China. Scand J Gastroenterol. 2008;43:1353–9.CrossRefPubMed
20.
Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, et al. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet. 2005;160:49–54.CrossRefPubMed
21.
Catarino RJ, Breda E, Coelho V, Pinto D, Sousa H, Lopes C, et al. Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma. Head Neck. 2006;28:603–8.CrossRefPubMed
22.
Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 1998;4:2411–8.PubMed
23.
Matthias C, Jahnke V, Jones PW, Hoban PR, Alldersea JE, Worrall SF, et al. Cyclin D1, glutathione S-transferase, and cytochrome P450 genotypes and outcome in patients with upper aerodigestive tract cancers: assessment of the importance of individual genes using multivariate analysis. Cancer Epidemiol Biomarkers Prev. 1999;8:815–23.PubMed
24.
Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61:6042–5.PubMed
25.
Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009;15:5338–49.PubMedCentralCrossRefPubMed
26.
Krupa R, Sobczuk A, Poplawski T, Wozniak K, Blasiak J. DNA damage and repair in endometrial cancer in correlation with the hOGG1 and RAD51 genes polymorphism. Mol Biol Rep. 2011;38:1163–70.PubMedCentralCrossRefPubMed
27.
Werbrouck J, De Ruyck K, Duprez F, Van Eijkeren M, Rietzschel E, Bekaert S, et al. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res. 2008;656:74–81.CrossRefPubMed
28.
Kaushal M, Chattopadhyay I, Phukan R, Purkayastha J, Mahanta J, Kapur S, et al. Contribution of germ line BRCA2 sequence alterations to risk of familial esophageal cancer in a high-risk area of India. Dis Esophagus. 2010;23:71–5.CrossRefPubMed
29.
30.
Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26:1457–64.CrossRefPubMed
31.
Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.PubMedCentralCrossRefPubMed
32.
Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, et al. Implication of BRCA2–26G > A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res. 2007;9:R71.PubMedCentralCrossRefPubMed
33.
Buchhop S, Gibson MK, Wang XW, Wagner P, Sturzbecher HW, Harris CC. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res. 1997;25:3868–74.PubMedCentralCrossRefPubMed
34.
Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010;28:2445–51.PubMedCentralCrossRefPubMed
35.
Briollais L, Wang Y, Rajendram I, Onay V, Shi E, Knight J, et al. Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario. BMC Med. 2007;5:22.PubMedCentralCrossRefPubMed
Metadata
Title
Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis
Authors
Mishi Kaushal Wasson
Pradeep Singh Chauhan
L. C. Singh
Dheeraj Katara
Jagannath Dev Sharma
Eric Zomawia
Amal Kataki
Sujala Kapur
Sunita Saxena
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1779-2

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Research Article

The mechanisms of 5-FU-PLA-O-CMC-NPS-mediated inhibition of the proliferation of colorectal cancer cell line SW480

Research Article

Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma

Research Article

Cleft lip and palate transmembrane protein 1 rs31489 polymorphism is associated with lung cancer risk: a meta-analysis

Research Article

High sensitivity of touch imprint cytology in young patients with invasive lobular carcinoma of the breast

Research Article

XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis

Research Article

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits